Batoclimab (IMVT-1401) for Graves' Ophthalmopathy Drug Landscape Report 2024: Market Size, Forecast, and Emerging Insights for 7MM 2019-2032
The "Batoclimab Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about batoclimab for Graves' ...
Frontiers18d
Advances in artificial intelligence in thyroid-associated ophthalmopathy
Thyroid-associated ophthalmopathy (TAO), also referred to as Graves’ ophthalmopathy, is a medical condition wherein ocular complications arise due to autoimmune thyroid illness. The diagnosis of TAO, ...
Medscape29d
Severe Graves' Ophthalmopathy After Retrobulbar Anesthesia for Cataract Extraction in a Patient With Mild Stable Thyroid Eye Disease
Finally, the improvement of ophthalmopathy occurred despite TSI levels remaining markedly elevated suggesting that beneficial effects of radiotherapy are not mediated by suppressing TSI production.
Pharmaceutical Technology1mon
Satralizumab by F. Hoffmann-La Roche for Graves’ Ophthalmopathy: Likelihood of Approval
Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Graves’ Ophthalmopathy. According to GlobalData, Phase III drugs for Graves’ Ophthalmopathy have a 50% ...